RLAY · Relay Therapeutics, Inc. · Stock research

‎# RLAY — Relay Therapeutics, Inc.

Current Thesis

The coverage-driven leg identified in the 2026-08-15 note is still running, and it is still being fed by maintenance revisions rather than new money. HC Wainwright reiterated Buy and raised its target to $29 on 2026-08-20 — the fourth upward revision in fourteen days, after Barclays $30 (2026-08-07), Citizens $26 (2026-08-10) and JP Morgan $31 (2026-08-14). What changed is what the tape did with it: the shares closed at $19.44 on 2026-08-21, 6.3% below the $20.75 52-week high, so the fourth raise did not produce a new high. That is one observation, not a trend, but it is the first time in this sequence that a target raise has not been met with a higher print.

The second change is insider supply. Two months at the same share counts reads as a scheduled monthly plan, not a discretionary exit — and it is still a standing monthly seller into a tape whose only new information is analyst arithmetic.

What an investor is buying: the distance between $19.44 and a published band of $26 (Citizens) to $31 (JP Morgan), bridged by Phase 3 execution disclosed in increments, on a balance sheet of $910.9M in cash and investments at 6/30/26 with runway guided into 2029 (Q2 release, 2026-08-06). No dated clinical event stands between here and year-end.

The narrative is maturing, closer to the saturated boundary than a month ago. Dating it: first-time initiations were 2026-07-08 (JP Morgan) and 2026-07-16 (Canaccord Genuity); every sell-side action since — 08-07, 08-10, 08-14, 08-20 — has been a raise on existing coverage. The last unanticipated clinical datapoint remains the ISSVA presentation of 2026-05-20.

Bullish and bearish views on Relay Therapeutics, Inc.

The model's bull view on Relay Therapeutics, Inc. (RLAY), in brief: Cash and investments of $910.9M at 6/30/26 versus $642.1M at 3/31/26, runway guided into 2029 (Q2 release, 2026-08-06). The bear view: Roughly $300M of at-the-market capacity remains available after the 2026-08-06 prospectus supplement expanded the program from $250M to $462,978,049, of which approximately $162,978,049 had already been sold. Both cases follow in full.

Bull Case

• Cash and investments of $910.9M at 6/30/26 versus $642.1M at 3/31/26, runway guided into 2029 (Q2 release, 2026-08-06). The Phase 3 readout does not have to be financed out of a distressed print.
• The efficacy anchor from ESMO TAT on 2026-03-16 is unmatched publicly: 11.1-month median PFS for zovegalisib + fulvestrant at the 400mg BID fed Phase 3 dose in heavily pre-treated patients, and 11.2 vs 11.0 months across kinase and non-kinase domain mutations, against roughly 5.5 months for alpelisib + fulvestrant in SOLAR-1.
• The frontline extension has data behind it, not just intent: 44% objective response rate for zovegalisib + atirmociclib (Pfizer) in median third-line PI3Kα-mutated HR+/HER2- breast cancer, with the Phase 3 in endocrine-sensitive patients slated to initiate early 2027 subject to regulatory feedback (2026-08-06 corporate update).
• Breakthrough Therapy Designation granted 2026-02-03 for the ReDiscover-2 population keeps an accelerated regulatory path open.
• Sponsorship has broadened rather than rotated: four firms raised targets between 2026-08-07 and 2026-08-20, and the lowest published target in that group ($26, Citizens) sits above the 2026-08-21 close of $19.44.
• ReInspire expansion cohorts in PIK3CA-driven vascular anomalies were opened per the 2026-08-06 update, following the 2026-05-20 ISSVA dataset (60% volumetric response across doses, no discontinuations for adverse events in roughly 20 efficacy-evaluable patients). There is no approved targeted therapy in that indication.

Bear Case

• Roughly $300M of at-the-market capacity remains available after the 2026-08-06 prospectus supplement expanded the program from $250M to $462,978,049, of which approximately $162,978,049 had already been sold. Sales go through TD Cowen at up to 3.0% commission and require no separate announcement on the day they occur.
• Insider distribution is now a two-month pattern at rising prices — with no offsetting open-market insider purchase in the same window.
• The next company-controlled checkpoint is a ReDiscover-2 enrollment update guided by year-end 2026, and the next hard clinical readout is 2027. Between 2026-08-23 and 2026-09-22 there is no dated company event.
• Q2 revenue of $350K missed the $872.7K consensus and EPS of $(0.41) missed $(0.39) (Benzinga summary, 2026-08-06). Quarterly R&D expense was $76.5M against a Q2 net loss of $83.7M — the operating burn is the reason the ATM exists.
• Scorpion Therapeutics' STX-478, inside Lilly, targets the same mutant-selective PI3Kα thesis. A competing dataset with comparable PFS and comparable hyperglycemia rates compresses the differentiation the $26–$31 band is built on.
• The revision cycle has an end. Once every covering firm has marked to the same band, the next sell-side action is statistically more likely to be a hold or a cut than another raise.

Setup & Price Structure

Reference close 2026-08-21: $19.44, with a 52-week high of $20.75 and a three-month price change of +43.7%. RSI(14) at 58.7 is mid-range — the June–August advance has not left an overbought reading, and it has not produced a momentum extreme to fade either.

The structure that matters is the $17.33 prior 52-week high, which converted to support after the June breakout and has floored the range since. Above it, the July–August trade has been a shelf roughly bracketed by the insider print range of $18.61 (2026-07-28) to $20.33 (2026-08-17) — a four-week band under the highs with declining incremental news. Losing $17.50 on a weekly close puts price back inside the pre-breakout range and removes the structural argument entirely; the four published targets would then be the only thing left holding the story up.

Crowding observables, stated without a verdict: four target raises inside fourteen days from firms already covering the name; a fourth raise (2026-08-20) that did not produce a new high; monthly 10b5-1 sales by both the CEO and CFO at successively higher prices; and roughly $300M of undrawn ATM capacity registered 4% below the 52-week high. There is no earnings date inside 30 days to force a resolution either way.

Catalyst Calendar (next 30 days)

• 2026-08-23 to 2026-09-22: no company-confirmed dated event. The window is empty; price action in it is flow and sector beta.
• ~2026-09 (est., monthly cadence): next scheduled 10b5-1 tranches from the CEO and CFO, if the July/August pattern holds. Observable only after the fact via Form 4.
• 2026-10-23 to 2026-10-27: ESMO Congress 2026, Madrid (esmo.org). No Relay presentation has been announced as of 2026-08-21; abstract titles typically surface roughly a week before. This is the venue where any updated zovegalisib dataset would most plausibly appear in 2026.
• ~2026-11-05 (est.): Q3 2026 results. First disclosure of shares actually issued under the expanded ATM and of Q3 burn against the "into 2029" runway.
• 2026-12-31: ReDiscover-2 enrollment update, guided by year-end on the 2026-08-06 call.

What Would Change Our Mind

The structure breaks if the post-June shelf goes. That is a weekly close below $17.50, which loses the $17.33 prior 52-week high that has floored every weekly close since the breakout; at that point the coverage-driven leg is over regardless of where the targets sit.

Three softer conditions would flip the read before price gets there. First, a prospectus filing or a Q3 share count showing material ATM issuance at or near $20 — that converts the analyst band from a target into an exit window for the company. Second, the year-end 2026 enrollment update arriving vague, slipped, or not at all: the only execution proof available before 2027 comes and goes with nothing checkable in it. Third, the revision cycle turning — a downgrade or target cut from any of the covering firms, or price trading up through $26–$31 with no new firm initiating, which would date the flip to saturated.

What would strengthen the case instead: an open-market insider purchase, a partner-driven event (Pfizer expanding beyond the atirmociclib supply arrangement), or a ReDiscover-2 enrollment update that pulls the Phase 3 readout forward from 2027.

Correlation Notes

• Sector gate: this is a pre-revenue clinical biotech with a 2027 readout, so it trades as high-beta XBI exposure between catalysts. XBI losing its 200-DMA de-rates the whole group irrespective of company-specific structure.
• Rate sensitivity: a $910.9M cash pile against zero product revenue makes the name a duration asset; long-end yield spikes hit it harder than they hit profitable pharma.
• Partner read-through: atirmociclib is Pfizer's CDK4 asset. Any change in Pfizer's CDK4 prioritisation reads directly into the frontline triplet leg slated for early 2027.
• Competitive read-through: Scorpion/Lilly STX-478 data is the single most direct comparator. A strong STX-478 print is a negative read for RLAY even with no RLAY news that day.
• Single-molecule concentration: zovegalisib carries both the breast-cancer and the vascular-anomalies legs, and RLY-4008 (FGFR2) is licensed out to Elevation Oncology, so a safety signal in either indication has no internal offset.